Mission: Cure
Mission: Cure is a 501(c)(3) nonprofit founded in 2017 that convenes patients, researchers, and biotech companies to accelerate curative treatments for chronic pancreatitis through AI-assisted drug repurposing, patient outcome financing, and clinical trial partnerships.
- Company typePrivate
- Founded2017
- HeadquartersAlexandria, United States
- Headcount1–10
- GTM typeB2B and B2C
- OfferingServices
What Mission: Cure does
Mission: Cure is a U.S.-registered 501(c)(3) nonprofit founded in 2017 and headquartered virtually in Providence, Rhode Island, focused exclusively on accelerating curative treatments for chronic pancreatitis. It operates as a multi-stakeholder alliance bringing together pancreatitis patients, caregivers, clinicians, academic researchers, biotechnology drug developers, and impact investors around a coordinated cure strategy. The organization delivers its mission through free patient education content (webinars, toolkits, patient stories, support groups), clinical trial navigation resources, and an advocacy program that links patients to research opportunities.
The organization's core technical contribution is the application of AI and statistical techniques to drug repurposing for chronic pancreatitis. In February 2019, Mission: Cure convened a four-month datathon with Elsevier (AI framework), the Pistoia Alliance, Cures Within Reach, and Cincinnati Children's Hospital (Dr. Bruce Aronow) that identified four existing approved drugs — Lacosamide, Dapsone, Rolipram, and Prednisolone — as potential pancreatitis treatments. Mission: Cure does not appear to operate proprietary technology infrastructure of its own; instead it leverages partner platforms and academic collaborators to advance its cure pipeline, including a December 2025 strategic collaboration with Cibus Therapeutics and Greenstone Biosciences to advance CBT-101 into clinical trials targeted for 2026.
Mission: Cure generates revenue through individual and corporate donations, foundation grants, peer-to-peer fundraising (Give Lively, Facebook Fundraisers), corporate sponsorships, and an innovative patient outcome financing model that combines venture philanthropy with impact investing to fund drug development. The organization holds a Charity Navigator Four Star Rating and Candid Platinum Transparency designation for 2025, indicating credible governance and reporting standards, although specific revenue figures are not publicly disclosed. Headcount is small (1–10 staff), and the organization runs as a lean virtual operation with a Co-Founder/CEO, VP of Translational Research, and seasonal interns.
Mission: Cure firmographics
Firmographics- Name
- Mission: Cure
- Legal name
- Mission: Cure
- Website
- https://mission-cure.org
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Mission: Cure is a 501(c)(3) nonprofit founded in 2017 that convenes patients, researchers, and biotech companies to accelerate curative treatments for chronic pancreatitis through AI-assisted drug repurposing, patient outcome financing, and clinical trial partnerships.
- Ownership category
- akta.pro rank
Mission: Cure industry classification
Industry- Product category
- Nonprofit Patient Advocacy Services
- NAICS
- Voluntary Health Organizations (813212), Grantmaking and Giving Services (8132)
- SIC
- Services-Health Services (8000), Services-Social Services (8300)
- akta.pro primary industry
- Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)
- akta.pro secondary industries
- Health & Medical Research Grantmaking Foundations (BPAGAKAL), Community Health, Prevention & Health Education (BPAGACAC)
Keywords
Where Mission: Cure is headquartered
LocationHeadquarters
- HQ city
- Alexandria
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Mission: Cure business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Revenue model
- Donations and Charitable Contributions: Mission: Cure generates revenue through individual donations, corporate sponsorships, and charitable contributions from foundations. The organization is a registered 501(c)(3) nonprofit with EIN 84-3043384, making donations tax-deductible.
- Impact Investing: Mission: Cure utilizes patient outcome financing and impact investing models to fund drug development and research initiatives, aligning financial returns with patient health outcomes.
- Corporate Partnerships and Sponsorships: The organization receives support through corporate sponsorship and partnership programs where companies can support Mission: Cure's mission while gaining association with the pancreatitis community.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Mission: Cure product offering
Product offeringCore offering
Mission: Cure is a patient advocacy nonprofit that funds drug development and provides free educational resources, webinars, support groups, and clinical trial information for chronic pancreatitis patients and caregivers. The organization also operates a patient outcome financing model that uses impact investing and venture philanthropy to fund research and drug development partnerships with biotechnology and pharmaceutical companies.
Product overview
Mission: Cure is a nonprofit organization founded in 2017 focused on curing pancreatitis through patient education, research advocacy, and innovative financing. Their offerings include a library of patient education webinars, personal story sharing platforms, clinical trial information resources, toolkits for patients and caregivers, support groups, and an innovative patient outcome financing model that uses impact investing to fund drug development. The organization serves as a hub connecting patients, caregivers, doctors, researchers, drug developers, and entrepreneurs in the pancreatitis community.
Differentiator
Problem solved
Functional benefit
Products and services
- Patient Education Webinars A library of free expert-led webinars covering pain management, nutrition, mental health, triglycerides, autoimmune pancreatitis, pediatric exocrine pancreatic insufficiency, and vitamin deficiencies for pancreatitis patients and caregivers.
- Pancreatitis Support Groups Community support resources that connect pancreatitis patients and caregivers with others affected by the disease for peer support and shared experience.
- Clinical Trials Information Resources that help patients find and join clinical trials for pancreatitis treatments, including a cure strategy overview and a research opportunity sharing platform.
- Pancreatitis Patient Toolkits Educational materials including a genetic testing toolkit, pain management resources, and nutrition guides designed for pancreatitis patients and caregivers.
- Patient Outcome Financing An innovative financing model that uses impact investing and venture philanthropy to fund pancreatitis research and drug development, aligning financial returns with patient health outcomes.
Quantifiable outcome
- 4 drug repurposing candidates identified for pancreatitis treatment through AI-based datathon
Companies that use Mission: Cure
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles4 records
Mission: Cure technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Mission: Cure partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core, minor and flagship.
- Cibus TherapeuticscoreStrategic collaboration to advance CBT-101, a novel therapy for chronic pancreatitis. The partnership combines drug development, stem cell, AI-based discovery, and patient advocacy to begin clinical trials in 2026 targeting an unmet medical need.
- Greenstone BiosciencescorePartnering with Cibus Therapeutics and Mission: Cure to develop next-generation treatments for pancreatic and gastrointestinal diseases using stem cell and AI-based discovery platforms.
- Ionis PharmaceuticalscorePartnership related to TRYNGOLZA (olezarsen), the first-ever FDA-approved treatment for Familial Chylomicronemia Syndrome (FCS), a genetic cause of pancreatitis.
- Arrowhead PharmaceuticalscorePartnership on FCS (Familial Chylomicronemia Syndrome) resources and New Drug Application for plozasiran targeting dangerously high triglyceride levels.
- IgG4ward! FoundationminorPartnership for autoimmune pancreatitis education and resources, with Katharine Provencher of IgG4ward! Foundation co-presenting webinars with Mission: Cure.
- InspireminorOnline health community platform that launched High Triglycerides Connect with support from Ionis, providing peer support for people with high triglycerides.
- Johns Hopkins MedicineflagshipMission: Cure provided initial funding to launch the Pancreatitis Pain Research Center. Collaboration to establish the Pancreatitis Pain Research Program studying and treating specific types of pain associated with chronic pancreatitis.
- Ariel Precision MedicinecoreCollaboration on genetic testing for pancreatitis, with Dr. Mark Haupt serving as CMO of Ariel Precision Medicine and contributing to Mission: Cure's genetics resources.
- American College of GastroenterologycoreCollaboration around ACG clinical guidelines for chronic pancreatitis diagnosis and management, with Mission: Cure applying these guidelines through their patient-centered care framework.
- ElsevierflagshipProvided innovative artificial intelligence framework for the 4-month datathon aimed at identifying potential treatments for chronic pancreatitis using AI and statistical techniques.
- Pistoia AlliancecoreNonprofit consortium of life science companies working to lower barriers to innovation, collaborated on the datathon to identify pancreatitis drug repurposing candidates.
- Cures Within ReachcoreNonprofit leader in research to apply already-approved drugs to treat new diseases, collaborated on identifying and advancing drug repurposing candidates for pancreatitis.
- Cincinnati Children's Hospital (Dr. Bruce Aronow)coreAcademic collaboration with Dr. Bruce Aronow who developed a computable data model network for chronic pancreatitis to help determine which drugs were most likely to correct biological problems.
Scale indicators3 records
Mission: Cure competitors and assessment
Company assessmentDirect peers
- Beyond Celiac: Patient advocacy nonprofit driving research and drug development for a specific disease through community engagement and partnerships. Comparable in disease-focused, patient-led model for accelerating treatments.
- Cystic Fibrosis Foundation: Voluntary health organization that pioneered venture philanthropy and patient outcome financing to fund drug development — the same playbook Mission: Cure is applying to pancreatitis. Highly comparable mission, financing model, and partner ecosystem.
- Parent Project Muscular Dystrophy: Disease-specific nonprofit that combines patient advocacy, research funding, and biotech partnership development. Comparable in venture philanthropy-style approach to advancing therapeutics for a single disease area.
- ALS Association: Disease-specific voluntary health organization funding research, providing patient services, and driving clinical trial enrollment. Highly comparable operating model and biotech partnership approach, applied to a different disease.
- National Pancreas Foundation: Patient advocacy and research funding nonprofit focused specifically on pancreatic diseases including pancreatitis. Directly comparable disease focus, patient community, and clinical/researcher resources.
- EveryLife Foundation for Rare Diseases: Rare disease advocacy and policy nonprofit accelerating therapeutic development through legislative and funding initiatives. Comparable in mission alignment with Mission: Cure's rare/orphan pancreatitis focus and biotech advocacy role.
- Pancreatic Cancer Action Network (PanCAN): Major pancreatic disease nonprofit driving research funding, clinical trial enrollment, and patient services. Comparable in disease adjacency, patient advocacy GTM, and biotech partnership model, though focused on oncology rather than pancreatitis.
- Cures Within Reach: Nonprofit leader in drug repurposing for new diseases — a direct collaborator with Mission: Cure on the 2019 datathon. Comparable in therapeutic strategy (repositioning approved drugs) and nonprofit research funding model.
Broad incumbents
- National Organization for Rare Disorders (NORD): Largest US rare disease umbrella organization with extensive grant programs, patient advocacy, and research funding. Comparable as a broad voluntary health organization with grantmaking infrastructure relevant to Mission: Cure's pancreatitis focus.
- Chan Zuckerberg Initiative — Rare As One Network: CZI's Rare As One Network funds and convenes rare disease patient organizations, of which Mission: Cure is a member. Comparable as a funder/convener ecosystem for rare disease nonprofits pursuing patient-led cures.
Market position
Strengths5 records
Weaknesses5 records
Key risks6 records
Key highlights7 records
Customer concentration
Mission: Cure social profiles
Digital presenceMission: Cure financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mission: Cure leadership team
Management profileNumber of profiles
Profiles3 records
Mission: Cure funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mission: Cure M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mission: Cure
What does Mission: Cure do?
Mission: Cure is a patient advocacy nonprofit that funds drug development and provides free educational resources, webinars, support groups, and clinical trial information for chronic pancreatitis patients and caregivers. The organization also operates a patient outcome financing model that uses impact investing and venture philanthropy to fund research and drug development partnerships with biotechnology and pharmaceutical companies.
Is Mission: Cure a public or private company?
Mission: Cure is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Mission: Cure founded?
Mission: Cure was founded in 2017. It employs 1 to 10 people.
Where is Mission: Cure based?
Mission: Cure is headquartered in Alexandria, United States, in the North America region.
How does Mission: Cure make money?
Three revenue lines are on record. Donations and Charitable Contributions are the primary driver. The others are impact Investing and corporate Partnerships and Sponsorships.
Who are Mission: Cure's main competitors?
Direct peers on record are Beyond Celiac, Cystic Fibrosis Foundation, Parent Project Muscular Dystrophy, ALS Association, National Pancreas Foundation, EveryLife Foundation for Rare Diseases, Pancreatic Cancer Action Network (PanCAN) and Cures Within Reach. Broad incumbents are National Organization for Rare Disorders (NORD) and Chan Zuckerberg Initiative — Rare As One Network.
Does Mission: Cure have an API?
No public API is recorded for Mission: Cure.
What industry is Mission: Cure in?
Mission: Cure's product category is Nonprofit Patient Advocacy Services. Its primary akta.pro industry code is BPAGACAA, Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS), with a secondary code of BPAGAKAL, Health & Medical Research Grantmaking Foundations. Its NAICS code is 813212 and its SIC code is 8000.